Table 3.

Retrospective trials included in the analysis showing the name of the author, year of publication, number of patients enrolled in the trial, the intervention that was tested and the outcome

First author	Year of publication	No of patients	Intervention and number of patients	Outcome of systemic therapy
Mitchell [34]	2000	22 resectable dediff CS	Doxorubicin based chemotherapy + surgery	1/5 > 90% necrosis after preoperative chemo
			5 preoperative chemotherapy and 6 postoperative, 11 no chemotherapy	5 year OS with chemotherapy 36%, without 0%
Dickey [35]	2004	42 local or advanced dediff CS	15 Surgery	5 year OS and median OS: with surgery 11.8% and 6.4 months
			22 surgery and chemotherapy 5 other
				With surgery and chemotherapy 4% and 8.4 months
Staals [36]	2006	102 local or advanced dediff central CS	68 Surgery	Median survival 18 vs 23 months (not significant)
			25 surgery + chemotherapy
			9 palliative care
Cesari [7]	2007	24 local or advanced mesenchymal CS	24 surgery of which:	10 year OS:
			5 + RT	Surgical remission 27%
			12 + chemotherapy	Non-surgical remission 0%
				Complete surgical remission 10 year DFS:
				With chemotherapy 76%, without 17%
Grimer [37]	2008	266 local and 71 advanced dediff CS	207 Surgery	Local disease
			90 chemotherapy	5 year OS:
			40 surgery + chemotherapy	With chemotherapy 33%, without 25% (p = 0.11)
				Advanced disease
				Median OS: With chemotherapy 7 months, without 3 months (not significant)
Dantonello [38]	2008	14 local mesenchymal CS	12 Surgery + chemotherapy	10 year OS 64%
			2 surgery + RT
Bernstein-Molho [39]	2012	9 advanced CS	Sirolimus + cyclophosphamide	OR 11%
				SD 56%
				PFS 15 months
Italiano [5]	2012	98 advanced CS	Doxorubicin based chemotherapy	OR 14%
				SD 31%
				PFS 5.3 months
				OS 19 months

CS chondrosarcoma, Dediff dedifferentiated, DFS disease free survival, OR objective response, OS overall survival, PFS progression free survival, RT radiotherapy, SD stable disease.